Revenue Breakdown
Composition ()
No data
Revenue Streams
Moderna Inc (MRNA) generates its revenue primarily from COVID, which accounts for 100.0% of total sales, equivalent to $114.00M. Understanding this concentration is critical for investors evaluating how MRNA navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Moderna Inc maintains a gross margin of 86.22%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -19.00%, while the net margin is -19.69%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MRNA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MRNA competes directly with industry leaders such as UTHR and ZLAB. With a market capitalization of $17.51B, it holds a significant position in the sector. When comparing efficiency, MRNA's gross margin of 86.22% stands against UTHR's 87.38% and ZLAB's 60.13%. Such benchmarking helps identify whether Moderna Inc is trading at a premium or discount relative to its financial performance.
